Insulin Aspart (rDNA Origin) Injection
Insulin aspart is a man-made, mealtime-type insulin used to improve blood sugar control in people with diabetes mellitus, available alone (NovoLog, Fiasp) or mixed with a longer-acting insulin (Insulin Aspart Protamine and Insulin Aspart Mix 70/30).
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 15 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Insulin aspart (NovoLog, Fiasp) is a rapid-acting mealtime insulin for diabetes that helps muscle and fat cells take in blood sugar and tells the liver to release less; on the U.S. market since about 2001, it is among the most widely used. Most people tolerate it well, noticing mild redness or itching where they inject and some weight gain. The one thing to watch is low blood sugar, which can come on suddenly and affect concentration and driving, so check your glucose as planned and learn your warning signs. Read the label before every injection, since mixing it up with a long-acting insulin is an easy, dangerous error.
Clinical pearls
- Inject it within 5 to 10 minutes before you eat, and do not skip the meal afterward.
- Rotate injection sites, because insulin injected into lumpy or dented skin absorbs unevenly and can swing your sugars.
- Beta-blockers, often taken for blood pressure, can mask low blood sugar warning signs, so check with your meter when unsure.
- On a pump, a failed infusion set can quickly raise sugar and ketones, so keep backup pens or syringes.
Patient information guide A plain-language walkthrough of Insulin Aspart (rDNA Origin) Injection, written from its FDA label.
What Insulin Aspart (rDNA Origin) Injection is used for
▾
Insulin aspart products are used to improve blood sugar control in diabetes mellitus.
- Insulin Aspart Protamine and Insulin Aspart Mix 70/30 (NovoLog Mix 70/30): improves blood sugar control in adults with diabetes mellitus.
- Mix 70/30 is not recommended for diabetic ketoacidosis.
- Mix 70/30 has fixed proportions of fast- and longer-acting insulin, so basal versus mealtime doses can’t be adjusted separately.
- Fiasp has been studied in adults and children with type 1 or type 2 diabetes.
How Insulin Aspart (rDNA Origin) Injection works
▾
Insulin aspart binds to insulin receptors on cells. This helps muscle and fat cells take up sugar from the blood and reduces sugar output from the liver. Insulin also slows fat and protein breakdown and supports protein building.
Insulin Aspart (rDNA Origin) Injection dosage
▾
Insulin aspart is generally injected under the skin shortly before a meal (within 5 to 10 minutes for NovoLog). It is usually used with an intermediate- or long-acting insulin.
- NovoLog can be used in compatible insulin pumps. Do not mix it with other insulins or diluents in the pump.
- Intravenous use is only under medical supervision.
- NovoLog may only be mixed with NPH insulin in a syringe. Draw up the NovoLog first and inject right away.
- Your dose is individualized and may change with activity, meals, illness, or kidney or liver function.
Dosing details from the FDA-approved label
From the Insulin Aspart (rDNA Origin) Injection prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Subcutaneous injection
- Inject subcutaneously within 5-10 minutes before a meal into the abdominal area, thigh, buttocks or upper arm
- Generally use in regimens with an intermediate- or long-acting insulin
- Rotate injection sites within the same region; dosage adjustments may be needed with changes in physical activity, meal patterns, renal or hepatic function or acute illness
- Continuous subcutaneous infusion (insulin pump)
- Administer by continuous subcutaneous infusion in a region recommended in the pump manufacturer's instructions
- Change the insulin in the reservoir at least every 7 days or according to the pump user manual, whichever is shorter
- Do not mix or dilute; do not expose insulin in the pump reservoir to temperatures greater than 98.6°F (37°C)
- Intravenous administration
- Dilute to concentrations from 0.05 unit/mL to 1 unit/mL insulin aspart in infusion systems using polypropylene infusion bags
- Only under medical supervision with close monitoring of blood glucose and potassium levels
- Mixing with other insulins (subcutaneous injection)
- May only be mixed with NPH insulin preparations
- Withdraw Insulin Aspart into the syringe first and inject immediately after mixing
- Do not mix with any other insulin in the insulin pump
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION See Full Prescribing Information for important preparation, administration, and dosage instructions ( 2.1, 2.2, 2.3, 2.4, 2.5 ). • Subcutaneous injection ( 2.2 ): o Inject subcutaneously within 5-10 minutes before a meal into the abdominal area, thigh, buttocks or upper arm. o Rotate injection sites within the same region from one injection to the next to reduce risk of lipodystrophy and localized cutaneous amyloidosis. o Should generally be used in regimens with an intermediate- or long-acting insulin. • Continuous Subcutaneous Infusion (Insulin Pump) ( 2.2 ): o Refer to the insulin infusion pump user manual to see if NovoLog (insulin aspart) can be used. Use in accordance with the insulin pump instructions for use. o Administer by continuous subcutaneous infusion using an insulin pump in a region recommended in the instructions from the pump manufacturer. o Rotate the injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. o Do not mix with other insulins or diluents in the pump. • Intravenous Administration ( 2.2 ) : o Dilute Insulin Aspart to concentrations from 0.05 unit/mL to 1 unit/mL insulin aspart in infusion systems using polypropylene infusion bags. o Insulin Aspart is stable in infusion fluids such as 0.9% Sodium Chloride Injection, USP. • Individualize and adjust the dosage of Insulin Aspart based on route of administration, the individual's metabolic needs, blood glucose monitoring results and glycemic control goal ( 2.4 ). • Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness ( 2.4 ). 2.1 Important Preparation and Administration Instructions • Always check insulin labels before administration. This product is NovoLog (insulin aspart) [see Warnings and Precautions ( 5.4 )] . • Inspect Insulin Aspart visually before use. It should appear clear and colorless. Do not use Insulin Aspart if particulate matter or coloration is seen. • In patients with visual impairment, use: o Insulin Aspart FlexPen with caution in those who may rely on audible clicks to dial their dose. o PenFill cartridges with caution.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Insulin Aspart (rDNA Origin) Injection side effects
▾
Common effects include:
Common side effects
- Low blood sugar (hypoglycemia), the most common one
- Injection or infusion site reactions (redness, pain, bruising, itching)
- Changes in the skin at injection sites (lipodystrophy)
- Weight gain
- Swelling from fluid retention (edema)
- Allergic skin reactions such as rash or hives
- Cold-like symptoms (nasopharyngitis, upper respiratory infection) in Fiasp trials
When to get medical help
- Severe low blood sugar: confusion, seizures, passing out. Get emergency help.
- Signs of a serious allergic reaction: widespread rash, swelling of the face, trouble breathing, fainting. Get emergency help and stop the insulin.
- Low potassium (hypokalemia), which can cause dangerous heart rhythm problems or breathing muscle weakness
- New swelling, weight gain or shortness of breath if you also take a thiazolidinedione (a diabetes pill such as pioglitazone), which can worsen heart failure
- High blood sugar or ketones if your insulin pump or infusion set fails. Switch to injections and call your provider.
- Lumps or dents in the skin at injection sites, or a lumpy skin patch (cutaneous amyloidosis)
Insulin Aspart (rDNA Origin) Injection warnings and precautions
▾
- Low blood sugar can be severe and life-threatening, causing seizures or unconsciousness.
- Low potassium can be life-threatening.
- Severe allergic reactions, including anaphylaxis, can occur.
- Combining with thiazolidinediones can cause fluid retention and heart failure.
- Insulin pump failure can quickly cause high blood sugar and ketoacidosis, so have backup insulin and injection training.
- Never share pens or needles, because blood-borne infections can spread.
Insulin Aspart (rDNA Origin) Injection interactions
▾
Many medicines change how insulin works or hide low blood sugar symptoms.
- Raise low blood sugar risk: other diabetes drugs, ACE inhibitors, angiotensin receptor blockers, fibrates, fluoxetine, MAO inhibitors, salicylates, octreotide, sulfonamide antibiotics.
- Weaken insulin: corticosteroids, diuretics, estrogens, oral contraceptives, atypical antipsychotics, protease inhibitors, thyroid hormones, sympathomimetics.
- Variable effect: alcohol, beta-blockers, clonidine, lithium, pentamidine.
- Mask low blood sugar signs: beta-blockers, clonidine, guanethidine, reserpine.
Interactions listed in the FDA-approved label
From the Insulin Aspart (rDNA Origin) Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics: May increase the risk of hypoglycemia. Dose adjustment and increased frequency of glucose monitoring may be required.
- Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones: May decrease the blood glucose lowering effect of insulin aspart. Dose adjustment and increased frequency of glucose monitoring may be required.
- Alcohol, beta-blockers, clonidine, lithium salts: May increase or decrease the blood glucose lowering effect of insulin aspart. Dose adjustment and increased frequency of glucose monitoring may be required.
- Pentamidine: May cause hypoglycemia, which may sometimes be followed by hyperglycemia. Dose adjustment and increased frequency of glucose monitoring may be required.
- Beta-blockers, clonidine, guanethidine, reserpine: May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.
Read the label’s full interactions text
7 DRUG INTERACTIONS The table below presents clinically significant drug interactions with Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Table 3: Clinically Significant Drug Interactions with Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when Insulin Aspart Protamine and Insulin Aspart is concomitantly administered with these drugs. Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Protamine and Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when Insulin Aspart Protamine and Insulin Aspart is concomitantly administered with these drugs. Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of Insulin Aspart Protamine and Insulin Aspart Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when Insulin Aspart Protamine and Insulin Aspart is concomitantly administered with these drugs.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Insulin Aspart (rDNA Origin) Injection
▾
- Do not use during low blood sugar or with a known allergy to insulin aspart or its ingredients.
- Kidney or liver impairment raises low blood sugar risk and may need dose changes.
- Older adults need conservative dosing.
- Children on Fiasp need close glucose monitoring.
- Pregnancy and breastfeeding: discuss with your prescriber. Poorly controlled diabetes in pregnancy carries risks.
Insulin Aspart (rDNA Origin) Injection overdose
▾
Too much insulin can cause low blood sugar and low potassium. Mild lows are usually treated with oral glucose. Severe lows with coma or seizures may need emergency glucagon or intravenous glucose, and monitoring continues because lows can return.
What Insulin Aspart (rDNA Origin) Injection does in the body
▾
After injection under the skin, insulin aspart’s strongest sugar-lowering effect occurs about 1 to 3 hours later. It lasts about 3 to 5 hours. Timing varies between people and from day to day, and is affected by injection site and exercise.
How your body processes Insulin Aspart (rDNA Origin) Injection
▾
After injection under the skin, insulin aspart reaches its peak level in about 40 to 50 minutes, faster than regular human insulin (80 to 120 minutes). It is absorbed to a similar extent as regular human insulin.
How to store Insulin Aspart (rDNA Origin) Injection
▾
Dispense in the original sealed carton with the enclosed Instructions for Use. Store unused NOVOLOG in a refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze NOVOLOG and do not use NOVOLOG if it has been frozen.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Insulin Aspart (rDNA Origin) Injection
239 supplements and herbal products have documented interactions with Insulin Aspart (rDNA Origin) Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 1
- Moderate · 208
- Minor · 30
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Insulin Aspart (rDNA Origin) Injection has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Insulin Aspart (rDNA Origin) Injection: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Insulin Aspart (rDNA Origin) Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What is this insulin for?
▾
When do I inject it?
▾
What side effect should I watch for most?
▾
Can I take it with my other medicines?
▾
Can I share my pen if I change the needle?
▾
What if I’m pregnant or breastfeeding?
▾
Is Insulin Aspart (rDNA Origin) Injection available over the counter?
▾
When was Insulin Aspart (rDNA Origin) Injection first available?
▾
Who makes Insulin Aspart (rDNA Origin) Injection?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Insulin Aspart (rDNA Origin) Injection on HelloPharmacist
Insulin Aspart (rDNA Origin) Injection forms and strengths (how it comes)
Insulin Aspart (rDNA Origin) Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Insulin Aspart Protamine and Insulin Aspart Mix 70/30 is used to improve blood sugar control in adults with diabetes mellitus.
- Insulin Aspart Protamine and Insulin Aspart Mix 70/30 is not recommended for diabetic ketoacidosis.
- NovoLog is injected under the skin 5 to 10 minutes before a meal, and injection sites should be rotated.
- NovoLog can be used in compatible insulin pumps and should not be mixed with other insulins in the pump.
- NovoLog may be given into a vein only under medical supervision, with close monitoring of blood sugar and potassium.
- Never share Fiasp pens, cartridges or cartridge devices between people.
Insulin Aspart (rDNA Origin) Injection on the U.S. market: products, makers and brands
How Insulin Aspart (rDNA Origin) Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
4 companies list 29 Insulin Aspart (rDNA Origin) Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2000. Brand names on the directory include Fiasp, Novolog, NovoLog Mix 70/30 and 6 more; the rest are generics.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Insulin Aspart (rDNA Origin) Injection is used (Medicaid data)
A general measure of how commonly Insulin Aspart (rDNA Origin) Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Insulin Aspart (rDNA Origin) Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Insulin Aspart (rDNA Origin) Injection prescribed? Of the 1,601 medications we measure, Insulin Aspart (rDNA Origin) Injection ranks #177 by Medicaid prescriptions — more than 89% of them.
Utilization by Insulin Aspart (rDNA Origin) Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
3 ML insulin aspart, human 100 UNT/ML Pen Injector Most dispensed
Summed across the 3 of 14 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1653202
insulin aspart, human 100 UNT/ML Injectable Solution
Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 311040
3 ML insulin aspart, human 100 UNT/ML Cartridge
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1653196
Niacinamide 3 ML insulin aspart, human 100 UNT/ML Pen Injector
Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2730172
Niacinamide insulin aspart, human 100 UNT/ML Injectable Solution
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2730174
1.6 ML insulin aspart, human 100 UNT/ML Cartridge
Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2642808
Niacinamide 3 ML insulin aspart, human 100 UNT/ML Cartridge
Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2730170
3 ML insulin aspart-xjhz 100 UNT/ML Pen Injector
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2720539
insulin aspart-xjhz 100 UNT/ML Injectable Solution
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2720523
Other Insulin Aspart (rDNA Origin) Injection products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)
Summed across the 6 of 20 listed NDC products with Medicaid activity.
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Insulin Aspart (rDNA Origin) Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 20 of 62 listed Insulin Aspart (rDNA Origin) Injection NDCs with Medicaid activity.
Compare Insulin Aspart (rDNA Origin) Injection products
A representative set of FDA-listed product records for Insulin Aspart (rDNA Origin) Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 100 [IU]/mL | Intravenous, Subcutaneous | A-S Medication Solutions × 5 listings | BLA | View NDC → |
| 100 [IU]/mL | Subcutaneous | A-S Medication Solutions × 2 listings | BLA | View NDC → |
| 100 [IU]/mL | Intravenous, Subcutaneous | Novo Nordisk × 6 listings | BLA | View NDC → |
| 100 [IU]/mL | Subcutaneous | Novo Nordisk × 8 listings | BLA | View NDC → |
| 100 [IU]/mL | Intravenous, Subcutaneous | Novo Nordisk Pharma, Inc. × 3 listings | BLA | View NDC → |
| 100 [IU]/mL | Subcutaneous | Novo Nordisk Pharma, Inc. × 2 listings | BLA | View NDC → |
| 100 [IU]/mL | Intravenous, Subcutaneous | Remedyrepack Inc. | BLA | View NDC → |
| 100 [IU]/mL | Subcutaneous | Remedyrepack Inc. × 2 listings | BLA | View NDC → |
Showing 29 of 29 products — FDA National Drug Code Directory. See every product, package size and price: browse all 29 Insulin Aspart (rDNA Origin) Injection NDCs →
Insulin Aspart (rDNA Origin) Injection side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Insulin Aspart (rDNA Origin) Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Insulin Aspart (rDNA Origin) Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Insulin Aspart (rDNA Origin) Injection FDA approval history
How Insulin Aspart (rDNA Origin) Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Insulin Aspart (rDNA Origin) Injection recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Insulin Aspart recalls since July 2021.
✅No Insulin Aspart recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 51428 3 dose forms · 13 strengths
-
Dose form (SCDF) Cartridge RxCUI 1653195No current FDA listingClinical drug / strength (SCD) Niacinamide 3 ML insulin aspart, human 100 UNT/MLRxCUI 27301701.6 ML insulin aspart, human 100 UNT/MLRxCUI 26428083 ML insulin aspart, human 100 UNT/MLRxCUI 1653196 -
Dose form (SCDF) Injectable Solution RxCUI 378914In current FDA listingsClinical drug / strength (SCD) Niacinamide insulin aspart, human 100 UNT/MLRxCUI 2730174insulin aspart-fsan 100 UNT/MLRxCUI 2748451insulin aspart-szjj 100 UNT/MLRxCUI 2705733insulin aspart-xjhz 100 UNT/MLRxCUI 2720523100 UNT/MLRxCUI 311040 -
Dose form (SCDF) Pen Injector RxCUI 1653201In current FDA listingsClinical drug / strength (SCD) Niacinamide 3 ML insulin aspart, human 100 UNT/MLRxCUI 27301723 ML insulin aspart, human 100 UNT/MLRxCUI 16532023 ML insulin aspart-fsan 100 UNT/MLRxCUI 27484593 ML insulin aspart-szjj 100 UNT/MLRxCUI 27057413 ML insulin aspart-xjhz 100 UNT/MLRxCUI 2720539
Look up RxCUI 51428 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Insulin Aspart (rDNA Origin) Injection supply and shortage status
Whether Insulin Aspart (rDNA Origin) Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Insulin Aspart (rDNA Origin) Injection costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Injection, Solution · Subcutaneous | 100 [IU]/mL | $6.92 per mL | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Insulin Aspart (rDNA Origin) Injection brand names
Insulin Aspart (rDNA Origin) Injection is sold under 9 brand names in the FDA directory — Fiasp, Novolog, NovoLog Mix 70/30, Merilog and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Insulin Aspart (rDNA Origin) Injection: manufacturers and labelers
4 companies list Insulin Aspart (rDNA Origin) Injection products with the FDA. By number of product records, the largest are Novo Nordisk, A-S Medication Solutions, Novo Nordisk Pharma, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Insulin Aspart (rDNA Origin) Injection drug class (RxNorm)
Insulin Aspart (rDNA Origin) Injection belongs to the Insulin Analog class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Insulin Aspart (rDNA Origin) Injection page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Novo Nordisk is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →